Clinical Outcome of Guillain-Barré Syndrome in 108 Children

Sen, Sandip; Kumar, Anil; Roy, Banasree

doi:10.1007/s13312-021-2302-7

Cited by 5 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical and demographic characteristics of our study cohort were similar to the previous studies. There was a significant male preponderance (62.8%) in our study population, which has been described in earlier studies also 8,9 . We found that the axonal variant of GBS was preceded by gastrointestinal infections and the demyelinating variant by upper respiratory tract infections, similar to the previous reports 9,10 …”

Section: Discussionsupporting

confidence: 92%

“…8,9 We found that the axonal variant of GBS was preceded by gastrointestinal infections and the demyelinating variant by upper respiratory tract infections, similar to the previous reports. 9,10 The most common clinical presentation observed in our study was paraparesis. The median (IQR) time from onset to peak weakness was 4 (3, 6) days, which was comparable with other studies.…”

Section: Discussionsupporting

confidence: 90%

“…There was a significant male preponderance (62.8%) in our study population, which has been described in earlier studies also. 8,9 We found that the axonal variant of GBS was preceded by gastrointestinal infections and the demyelinating variant by upper respiratory tract infections, similar to the previous reports. 9,10 The most common clinical presentation observed in our study was paraparesis.…”

Section: Discussionsupporting

confidence: 90%

See 2 more Smart Citations

Assessment of neurological sequelae and new‐onset symptoms in the long‐term follow‐up of paediatric Guillain–Barre syndrome: A longitudinal study from India

Sugumar

Chidambaram

Gunasekaran

2022

J Paediatrics Child Health

View full text Add to dashboard Cite

Background Guillain–Barre syndrome (GBS) is the commonest cause of acute flaccid paralysis in children. There is a paucity of studies that assess the long‐term outcome of paediatric GBS. Aim To assess the frequency of neurological sequelae and the new‐onset symptoms in the long‐term follow‐up of paediatric GBS and to identify the risk factors associated with them. Methods This longitudinal study involved 78 children with GBS treated between January 2015 and 2021. The parents of those children were contacted to visit the hospital for a detailed neurological examination and to look for new‐onset symptoms after the initial treatment for GBS. Results Of the 78 children, acute inflammatory demyelinating polyradiculoneuropathy, acute motor axonal neuropathy, and acute motor‐sensory axonal neuropathy variants were observed in 30 (38.5%), 27 (34.6%) and 11 (14.1%) children, respectively. The median (interquartile range (IQR)) duration of follow‐up was 3 (2, 4.5) years. The median (IQR) time to independent ambulation was 30 (13.5, 105) days. The neurological sequelae were found in 22 (28.2%) children. GBS disability score at admission (odds ratio (OR) = 4.6; 95% confidence interval (CI): 1.1–19.8; P = 0.04) and axonal variant of GBS (OR = 4.1; 95% CI: 1.5–20.8; P = 0.04) were found to be independent predictors of neurologic sequelae. A total of 28 children experienced new‐onset symptoms after GBS, with frequent falls while running and fatigue being the predominant symptoms. Those children with demyelinating variant achieved independent ambulation earlier than the axonal group on survival analysis (log‐rank P value = 0.04). Conclusion The presence of neurological sequelae and new‐onset symptoms were found in 28.2 and 35% of the GBS children, respectively. High GBS disability score at admission and axonal variant of GBS were independent predictors of neurological sequelae. Knowledge about these would help in devising a plan for rehabilitation.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Assessment of neurological sequelae and new‐onset symptoms in the long‐term follow‐up of paediatric Guillain–Barre syndrome: A longitudinal study from India

Sugumar

Chidambaram

Gunasekaran

2022

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…[ 37 ] In studies from India, need for artificial ventilation, delay in independent walking, inexcitable nerves on conduction testing, and axonal subtype have been associated with poorer outcomes. [ 38 39 ]…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India

Vishnu¹,

Garg²,

Dhamija³

et al. 2022

Annals of Indian Academy of Neurology

View full text Add to dashboard Cite

Objective: To study impact of COVID-19 pandemic on frequency, clinical/electrophysiological profile and treatment outcomes in pediatric Guillain-Barré syndrome (GBS). Background: GBS is the most frequent cause of pediatric acute flaccid paralysis. The effect of the COVID-19 pandemic on pediatric GBS is unclear in the literature. Methods: We conducted an ambispective, multicentric, cohort study involving 12 of 27 centres in GBS Consortium, during two periods: pre-COVID-19 (March-August 2019) and during COVID-19 (March-August 2020). Children ≤12 years who satisfied National Institute of Neurological Diseases and Stroke criteria for GBS/variants were enrolled. Details pertaining to clinical/laboratory parameters, treatment and outcomes (modified Rankin Scale (mRS) at discharge, GBS Disability score at discharge and 3 months) were analysed. Results: We enrolled 33 children in 2019 and 10 in 2020. Children in 2020 were older (median 10.4 [interquartile range 6.75–11.25] years versus 5 (2.5–8.4) years; P = 0.022) and had more sensory symptoms (50% versus 18.2%; P = 0.043). The 2020 group had relatively favourable mRS at discharge (median 1 (1–3.5) versus 3 (2–4); P = 0.042) and GBS disability score at 3 months (median 0 (0–0.75) versus 2 (0–3); P = 0.009) compared to 2019. Multivariate analysis revealed bowel involvement ( P = 0.000) and ventilatory support ( P = 0.001) as independent predictors of disability. No child in 2020 had preceding/concurrent SARS-CoV2 infection. Conclusions: The COVID-19 pandemic led to a marked decline in pediatric GBS presenting to hospitals. Antecedent illnesses, clinical and electrophysiological profile of GBS remained largely unchanged from the pre-pandemic era.

show abstract

“…Two of the identified studies came from the same centre and the study with the shorter duration of study period was excluded. The relevant data is summarized in Supplementary Table 3 [9][10][11][12][13][25][26][27][28][29][30][31][32].…”

Section: Literature Reviewmentioning

confidence: 99%

Guillain-Barré syndrome in children – High occurrence of Miller Fisher syndrome in East Asian region

Chiu

Chan²,

Yau³

et al. 2022

Brain and Development

View full text Add to dashboard Cite

Clinical Outcome of Guillain-Barré Syndrome in 108 Children

Cited by 5 publications

References 14 publications

Assessment of neurological sequelae and new‐onset symptoms in the long‐term follow‐up of paediatric Guillain–Barre syndrome: A longitudinal study from India

Assessment of neurological sequelae and new‐onset symptoms in the long‐term follow‐up of paediatric Guillain–Barre syndrome: A longitudinal study from India

Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India

Guillain-Barré syndrome in children – High occurrence of Miller Fisher syndrome in East Asian region

Contact Info

Product

Resources

About